罗氟司特的功效及作用介绍

Introduction to the efficacy and role of Roflumilast: Roflumilast is a phosphodiesterase-4 (PDE-4) inhibitor. Phosphodiesterase is a family of enzymes including at least 11 subtypes of enzymes, which can catalyze the decomposition of the messenger molecules cyclic adenosine monophosphate and/or cyclic guanosine monophosphate. Roflumilast is used to treat bronchitis-related cough and mucus excess in patients with severe COPD. Roflumilast is approved for the treatment of severe COPD and all severities of COPD.

Clinical trials have confirmed that roflumilast can reduce the frequency of acute exacerbations and improve lung function in patients with moderate to severe COPD. The research team studied nearly 2,000 patients. The patients were randomly treated with roflumilast or placebo, and the patients were also fixedly inhaled glucocorticoids and long-acting β2 receptor agonists. Tiotropium bromide is allowed.

After a 1-year study, Poisson regression analysis showed that compared with placebo, the proportion of moderate to severe COPD exacerbations decreased by 13.2% in the roflumilast group, but there was no significant difference between the two groups. However, a predefined sensitivity analysis using negative binomial regression showed that the difference was significant (14.2%, P=0.04).

Additionally, roflumilast consistently improved post-bronchodilator lung function (56 mL) compared with placebo. The reporting rate of adverse events was 67% in the treatment group and 59% in the placebo group. Patients in the placebo group had more COPD exacerbations (19% vs 15%), but patients in the roflumilast group had more diarrhea, weight loss, and nausea. More patients in the roflumilast group were aware of withdrawing from the study due to adverse events (11% vs 5%).

For more drug information about roflumilast, please contact us for consultation.

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.

Recommended hot articles: